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Abstract
Background: Human herpesvirus-8 (HHV-8) is the etiological agent of Kaposi’s sarcoma (KS) and of some
lymphoproliferative disorders of B cells. Most malignancies develop after long-lasting viral dormancy, and a preventing
role for both humoral and cellular immune control is suggested by the high frequency of these pathologies in
immunosuppressed patients. B cells, macrophages and dendritic cells of peripheral lymphoid organs and blood represent
the major reservoir of HHV-8. Due to the dual role of B cells in HHV-8 infection, both as virus reservoir and as agents of
humoral immune control, we analyzed the subset distribution and the functional state of peripheral blood B cells in HHV-8-
infected individuals with and without cKS.
Methodology/Principal Findings: Circulating B cells and their subsets were analyzed by 6-color flow cytometry in the
following groups: 1- patients HHV-8 positive with classic KS (cKS) (n = 47); 2- subjects HHV-8 positive and cKS negative (HSP)
(n = 10); 3- healthy controls, HHV-8 negative and cKS negative (HC) (n = 43). The number of B cells belonging to the
preimmune/natural effector compartment, including transitional, pre-naı¨ve, naı¨ve and MZ-like subsets, was significantly
higher among HHV-8 positive subjects, with or without cKS, while was comparable to healthy controls in the antigen-
experienced T-cell dependent compartment. The increased number of preimmune/natural effector B cells was associated
with increased resistance to spontaneous apoptosis, while it did not correlate with HHV-8 viral load.
Conclusions/Significance: Our results indicate that long-lasting HHV-8 infection promotes an imbalance in peripheral B cell
subsets, perturbing the equilibrium between earlier and later steps of maturation and activation processes. This observation
may broaden our understanding of the complex interplay between viral and immune factors leading HHV-8-infected
individuals to develop HHV-8-associated malignancies.
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Introduction
Human herpesvirus 8 (HHV-8) is a gammaherpesvirus
etiologically linked to several malignancies such as Kaposi’s
Sarcoma (KS), primary effusion lymphoma (PEL), and the
plasmablastic form of multicentric Castleman’s disease (MCD)
[1–3]. After clearance of the initial infection, HHV-8 establishes
latent infection in multiple cell types [2,4–7], and it is usually
detectable in malignant cells of HHV-8-related tumors. KS, a
highly vascularized tumor that manifests as a multifocal angio-
proliferative disease of the skin and mucosa, is the most frequent
HHV-8 associated malignancy. Central to KS pathogenesis is a
hyperproliferation of spindle-shaped cells, that are thought to be of
endothelial origin and assume the characteristic spindle shape
upon infection with HHV-8. According to the multifocal nature of
KS, we recently demonstrated that circulating endothelial
progenitor cells cultured from the peripheral blood of cKS
patients are infected by HHV-8, support viral productive
replication and may therefore represent putative precursors of
KS spindle cells [8]. In KS patients, B cells of peripheral lymphoid
organs and blood represent a major virus reservoir endowed with
the ability to sustain the lytic reactivation and dissemination of the
virus [9–11]. Lymphoproliferative disorders of B cell origin,
including PEL and MCD can occur concomitantly with KS,
confirming the existence of a deep pathogenetic linkage between
these malignancies [12].
The persistence of HHV-8 infection is the result of a delicate
balance between immune control, viral latency, viral reactivation
and persistent replication. Only a minor proportion of infected
hosts eventually develop malignancies due to immune breakdown.
Indeed, despite the high prevalence of HHV-8 infection (24.1%
among Italian population) [13], the majority of HHV-8-positive
subjects do not develop clinically evident malignancies. It is not
currently understood which components of the immune responses
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are essential for controlling the progression from asymptomatic
HHV-8 infection to development of KS. The existing data suggest
that both humoral and cellular immune responses are needed; in
particular the humoral response may be of vital importance in
conditions of transitory or permanent reduced T cell function [14].
Taken togheter, these observations emphasize the central and
conflicting role of B cells both in the maintenance as well as in the
immune control of HHV-8 infection.
Peripheral B cells are morphologically homogenous, but their
surface phenotypes, anatomic localization, and functional proper-
ties reveal a great level of complexity, which may be disrupted by
viral infection and inflammation. Immature B cells exit the bone
marrow and in the periphery they mature via transitional stages
into either mature naı¨ve or marginal zone (MZ) B cells, which
have mixed attributes of naı¨ve and memory B cells [15]. Because
transitional B cells and MZ B cells may respond to T cell-
independent antigens, they are indicated as natural effector cells
[16]. Together with mature naı¨ve B cells they constitute the
preimmune/natural effector compartment. Upon activation by T
helper-dependent antigens, mature naı¨ve B cells progress into
switched and IgM activated/memory B cells. These cells represent
the compartment of antigen-experienced cells [17]. A complex
regulation of several negative and positive selection checkpoints
usually controls peripheral B cell development [18]. At present,
abnormalities in one or more B cell subsets have been found across
a broad range of infectious and non-infectious diseases [19–22].
HHV-8 is a good potential candidate as B cell disregulating agent,
because it is able to influence the fate and function of B cells
through a number of viral proteins that affect B cell development,
allow infected B cells to escape from the control of the immune
system, and trigger clonal B cell proliferation by affecting B cell
cycle check-points and by mimicking cell signals that control cell
proliferation [2].
In order to better understand the role of B cells in chronic
HHV-8 infection and associated malignancies, in this study we
fully characterized peripheral B cells in HHV-8 positive patients
with or without KS compared with healthy controls. To avoid the
interference of confounding factors related to iatrogenic or AIDS-
related KS, we studied patients affected by the classic, Mediter-
ranean variant of the disease [1]. We showed that cKS patients
have increased number of circulating B cells, characterized by an
expansion of transitional, pre-naı¨ve, naı¨ve and MZ-like cells, all of
which showed an increased resistance to apoptosis. Antigen-
experienced memory B cell subsets appeared unaffected. No signs
of increased B cell activation nor increased incidence of
monoclonal B cell expansions were observed. We observed
changes in B cell subsets similar to those found in cKS in the
group of subjects with chronic HHV-8 infection without KS,
suggesting that HHV-8 infection per se may be responsible for
perturbation of B cell homeostasis in KS patients.
Abnormalities in B cell subsets, with altered equilibrium
between earlier and later steps of maturation and activation
processes, have never been described in HHV-8 infected patients;
we suggest that these observations may open the way to a better
understanding of the role of inflammation and immunity in the
control of gammaherpesvirus infections and their neoplastic
outcomes.
Results
Total B cells and their transitional, pre-naı¨ve, naı¨ve and
MZ-like subsets are expanded in cKS patients
We examined the frequency and number of B cells and their
subsets in the peripheral blood of 47 cKS patients compared with
43 HCs, by using 6-color flow cytometry. As shown in Figure 1, B
cells were identified in PB samples as CD19+. Gated on B cells,
CD272 and CD27+ B cells were defined. Within CD272 cells,
transitional B cells were identified as CD5+CD38hi cells, pre-naı¨ve
B cells as CD5+CD38int, unswitched naı¨ve B cells as CD52Ig-
D+IgM+, CD272 memory B cells as CD52IgD2IgM2 cells
[23,24]. Within CD27+ cells, switched memory B cells were
identified as IgD2IgM2 cells, IgM-only memory B cells as
IgD2IgM+ and MZ-like B cells as IgDloIgM+ cells [25–27].
The frequency of B cells within lymphocytes in aged HCs was
6.7% 60.5, as expected [28,29], and it was significantly higher in
cKS patients (10.9% 61.1; P,0.001). As shown in Figure 2, the
absolute number of B lymphocytes was accordingly expanded in
cKS patients than in HCs (P= 0.02). To more precisely define
the phenotype of the expanded populations we examined the
distribution of B cells along the various steps of peripheral B cell
maturation and differentiation. The frequency of CD272 B
lymphocytes was significantly higher in cKS than HCs (73.6%
62.1 vs 67.1% 62.6; P,0.05). This resulted in a significant
increase of the absolute number of CD272 but not CD27+ B cells
(Figure 2). As shown in the same figure, the absolute number of
transitional, pre-naı¨ve, naı¨ve and MZ-like B cells, all composing
the peripheral preimmune compartment, resulted significantly
higher in cKS patients than HCs (P= 0.002, P,0.0001, P,0.05
and P,0.05, respectively). On the contrary, the size of memory
B subsets, including IgM-only, isotype-switched and CD272
memory B cells, did not change between cKS patients and
healthy controls. No correlation was observed between changes
in B cell subset distribution and the clinical stage or evolution of
KS.
The expanded B cell subsets from cKS patients show
increased resistance to spontaneous apoptosis and
unaffected in vivo turnover
To investigate the mechanisms possibly underlying the expan-
sion of distinct B cell subsets in cKS patients, we examined two cell
parameters that can impact on the size of cell populations and that
can be measured in the periphery: cell apoptosis and cell turnover.
The level of spontaneous apoptosis of cultured B cells, as
detected by annexin V binding (Figure 3A), was significantly lower
in cKS patients than in healthy donors (P,0.05) (Figure 3B). As
shown in the same figure, a significantly lower apoptosis of cKS
cells was observed in CD272 cells (P,0.02), mainly composed of
transitional, pre-naı¨ve and naı¨ve B cells, as well as in CD27+IgDlo
cells (P,0.01), consisting of MZ-like B cells. Because all the above
populations were expanded indeed in cKS, it may be argued that
resistance to apoptosis may contribute at least in part to the
perturbation of B cell homeostasis observed in our patients.
Accordingly, CD27+IgD2cells that mainly consist of switched
memory B cells and did not vary between patients and controls,
did not show differences between groups in sensitivity to apoptosis.
The analysis of cell apoptosis gated on different B cell subsets also
showed that both in patients and controls the frequency of
apoptotic cells was lower in CD272 than CD27+ subsets, as
expected [30].
To estimate the in vivo turnover of B cells, we analyzed the
expression of Ki67, a nuclear antigen that identifies recently
divided cells. A representative flow cytometric analysis is shown in
Figure 3C. The proportion of Ki67+ cells was higher within
CD27+ than CD272 B cells, as expected [31]. As shown in Fig. 3D,
the percentage of Ki67+ cells among total B cells, as well as
CD272 and CD27+ B cells did not differ between patients and
controls, making unlikely the possibility that the expansion of
Circulating B Cells in Chronic HHV-8 Infection
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distinct CD272 subsets and MZ-like B cells observed in our cKS
patients may rely on increased spontaneous turnover.
B cells from cKS patients have a resting phenotype
We further investigated the state of activation of B cells in KS
patients. Common manifestations of B cell hyperreactivity, like
hypergammaglobulinemia and increased frequency of autoanti-
bodies, were lacking (gammaglobulinemia in cKS patients and
HCs: 17.3% 60.6 and 16.7% 60.8, respectively; positive ANA in
cKS patients and HCs: 21% and 18%, respectively). We also
examined the expression of activation markers that may be up-
regulated on B lymphocytes upon chronic antigenic or polyclonal
stimulation. In particular, we analyzed the expression of the
costimulatory molecules CD80 and CD86 and of HLA-DR. As
shown in Figure 4, the intensity of expression of both
costimulatory molecules, expressed as mean fluorescence intensity
(MFI), was significantly lower on B cells from cKS patients than
HCs (P,0.002 and P,0.005 for CD80 and CD86, respectively).
The lower CD80 and CD86 expression was equally evident on B
cells of the expanded CD272 compartment and on CD27+ B cells,
although in this latter case the difference did not reach the
statistical significance. As shown in the same Figure, also the
expression of HLA-DR molecules tended to be lower on B cells
from KS patients than HCs. We further analyzed B cell expression
of CD20, a putative calcium channel that is down-regulated upon
B cell activation and that is expressed by the majority of human B-
cell lymphomas and leukemias [32,33]. According to their
immunophenotype indicative for a state of lower activation, B
lymphocytes from cKS patients expressed higher surface levels of
the molecule CD20 (P,0.001) (Figure 4). As observed for the
other activation markers, the higher expression of CD20 was quite
evident on CD272 as well as CD27+ B cells (P,0.001 and
P,0.0001, respectively). Similar results were obtained when the
frequency of B cells expressing the activation markers, rather than
MFI of their expression, was considered. No correlation was
observed between the activation of B cells and the clinical stage or
evolution of KS.
The frequency of monoclonal B cell expansions is not
increased in cKS patients
Because chronic HHV-8 infection may result in the develop-
ment of lymphoproliferative disorders, we further characterized B
cells to reveal a possible increased frequency of monoclonal B cell
expansions in our cKS patients. To this aim, we analyzed the
immunophenotype of B cells and evaluated the k/l light chain
ratio in cKS patients and HCs, according to the diagnostic criteria
proposed for monoclonal B lymphocytosis (MBL) [34,35]. In
particular, CLL-like MBL was defined based on the distinct
CD5brightCD20dim expression pattern on CD19+ B cells. Atypical
CLL-like and non-CLL-like MBL were defined based on the
occurrence of an unbalanced k/l ratio (more than 3:1 or less than
1:3) within CD5+ and CD52 B cells, respectively. Following this
strategy, we identified MBL in 4 of 43 HCs (9.3%; 1 CLL-like, 2
atypical CCL-like and 1 non-CLL-like MBL), as expected [34,35].
Moreover, we identified MBL in 2 of 47 cKS patents (4.3%; 1
CLL-like and 1 non-CLL-like MBL), thus indicating that cKS
patients do not have an increased incidence of monoclonal B cell
expansions. k light chain restriction was observed in 2 MBL clones
(2 HCs), l light chain restriction in 2 clones (1 HC and 1 cKS
patient), while negativity for both light chains was evident in the
remaining 2 cases.
Healthy HHV-8 seropositive (HSP) controls have changes
in B cells similar to those observed in cKS patients
To investigate whether the changes observed in circulating B
cells from cKS patients were secondary to HHV-8 infection per se,
or whether they were related to the presence of the tumor, we
included in our study ten age- and sex-matched HSP controls
without KS. We analyzed the number of B cells and their subsets
and the state of activation of B cells in HSP subjects compared
Figure 1. Identification of B cell subsets in the peripheral blood. Gating strategy used to identify circulating B lymphocytes and their subsets
by flow cytometry. Peripheral blood samples from cKS patients, HSP subjects and HCs were stained as described in Methods. B cells were identified as
CD19+ cells and further gated based on their CD27 surface expression. Gated on CD272 B cells, transitional and pre-naı¨ve B lymphocytes were
identified as CD5+CD38hi and CD5+CD38int cells, respectively. Gated on CD272CD52 B cells, naı¨ve and CD272 memory B lymphocytes were identified
as IgD+IgM+ and IgD2IgM2 cells, respectively. Gated on CD27+ B cells, switched memory, IgM-only memory and MZ-like B lymphocytes were
identified as IgD2IgM2, IgD2IgM+ and IgDloIgM+ cells, respectively. A representative flow cytometric analysis is shown.
doi:10.1371/journal.pone.0015029.g001
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with HCs and cKS patients. As reported in Table 1, HSP controls
showed changes in B cells that were similar to those observed in
cKS patients, although they were evident at a lesser extent. In
particular, HSP had higher number of total B cells than HCs
(P,0.01); similarly to what we observed in cKS patients, the
expansion of B cells in HSP controls was mainly restricted to the
CD272 population, that was markedly increased in HSP
compared with HCs (P,0.002). As observed in cKS patients,
HSP controls showed expanded transitional, pre-naı¨ve, naı¨ve and
MZ-like B cells, while the number of IgM-only, switched and
CD272 memory B cells was unaffected. To further investigate
whether B cells from HSP controls also showed the immunophe-
notypic changes observed in cKS patients indicative for a state of
lower activation, we analyzed B cell expression of CD80 and
CD86 and observed indeed that the intensity of expression of both
costimulatory molecules, expressed as MFI, was significantly lower
on B cells from HSP than HCs (P,0.02 and P,0.05 for CD80
and CD86, respectively) (Table 1). All together, these results
suggest that the perturbation of B cell homeostasis occurring in KS
patients is related to HHV-8 infection per se, as the presence of
KS is not a condition strictly required to induce the unbalance of
peripheral B cell subsets.
Figure 2. B cells and their non-memory subsets are increased in patients with cKS. The number of total B cells and CD272 B cells was
significantly higher in cKS patients (grey bars) than HCs (white bars). All the subsets composing the preimmune/natural effector compartment,
namely transitional, pre-naı¨ve, naı¨ve and MZ-like B lymphocytes, were increased in cKS patients, while the subsets composing the antigen-
experienced T cell-dependent compartment, namely IgM-only, switched and CD272 memory B cells, were unaffected. Data shown as mean 6 SE. P-
values calculated using the Student t test for independent samples. *P,.05; **P,.01; ***P,.001.
doi:10.1371/journal.pone.0015029.g002
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Figure 3. B cells from cKS patients show increased resistance to spontaneous apoptosis and unaffected in vivo turnover. Apoptotic
cells were detected by annexin V binding after 24 h culture in unstimulated conditions. A, representative flow cytometric analysis showing annexin V
binding gated on total B cells, CD272, MZ-like (CD27+IgDlo) and switched memory (CD27+IgD2) B cells, as indicated; comparison between one HC
(upper row) and one cKS patient (lower row). B, B cells from cKS patients (grey bars) showed significantly lower annexinV binding than B cells from
HCs (white bars); this lower annexin V binding was evident on CD272 and MZ-like (CD27+IgDlo) B cells, roughly composing the preimmune/natural
Circulating B Cells in Chronic HHV-8 Infection
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Changes in B cells from cKS patients and HSP controls do
not correlate with HHV-8 load
To evaluate whether the entity of B cell alterations observed in
cKS patients and HSP controls was related to HHV-8 viral load,
we analyzed possible correlations between the number of B cells or
their subsets and the viral gEq measured in plasma. No correlation
was observed between the count of either total, CD272, CD27+ B
cells or their subsets and plasmatic HHV-8 gEq. To further
investigate a possible role of B cell infection in promoting the
expansion of B cells and their subsets, we selected 7 cKS patients
and 6 HSP controls with B cell count either over the 75th
percentile or under the 25th percentile calculated for each group,
and determined the presence of HHV-8 gEq in their PBMCs and
isolated B cell and non-B fractions. As reported in Table 2, B cells
from 6 of 7 cKS patients and from 3 of 6 HSP controls were found
to harbor HHV-8 DNA sequences (6–475 HHV-8 gEq/105 cells).
HHV-8 DNA was detected in B cells from 5 of 7 subjects with B
cell expansion and from 4 of 6 subjects without expansion;
moreover, the number of HHV-8 gEq did not differ between
individuals with or without B cell expansions, thus indicating a
lack of correlation between B cell viral infection and B cell
changes. Accordingly, no correlation was observed between anti-
HHV-8 antibody titres and B cell changes.
Changes in B cells from cKS patients do not correlate
with the plasmatic levels IL-6 and IL-7
To evaluate whether the changes in B cells observed in our
patients could be driven at least in part by cytokines known to
affect the growth and differentiation of B lymphocytes, we
measured the plasmatic levels of IL-6 and IL-7 in our samples.
Detectable, low levels of IL-6 were found in 67% of the cKS
patients (mean 6 SE: 7.961.7 pg/ml) and 30% of the healthy
controls (4.961.9 pg/ml) and did not significantly differ between
groups. Also the plasmatic levels of IL-7, detected in all the
samples, were similar in cKS patients and controls (8.661.0 and
7.160.7 pg/ml, respectively). No correlation was observed
between the number of B cells or their subsets and the plasmatic
levels of cytokines.
Discussion
In this study we characterized circulating B cells in patients with
cKS to investigate whether HHV-8, which is the etiologic agent of
KS and has tropism for many cell types including B cells, may
affect the number and/or the immune phenotype of these cells. To
avoid the confounding effects of other concomitant viral infections
or immunosuppressive agents, we included in the study only
patients with cKS and observed that B cells from these patients
differ in many aspects from those of matched healthy controls
(HC). Moreover, to ascertain whether changes in B cells occurring
in KS patients were reasonably secondary to HHV-8 infection per
se, we included a group of healthy HHV-8-seropositive (HSP)
controls lacking KS.
Using cellular markers that enable the classification of B cells
into distinct subsets, we analyzed B cells belonging to either the
preimmune/natural effector compartment or the antigen-experi-
enced T helper-dependent compartment. Within the preimmune/
Figure 4. B cells from cKS patients show a low state of activation. B cells from cKS patients (grey bars) expressed lower levels of the
costimulatory molecules CD80 and CD86 and higher levels of CD20 than B cells from HCs (white bars). The expression of the indicated markers on
total B cells and their CD272 and CD27+ subsets is shown. Data presented as mean 6 SE of mean fluorescence intensity (MFI) values. P-values
calculated using the Student t test for independent samples. *P,.05; **P,.01; ***P,.001.
doi:10.1371/journal.pone.0015029.g004
effector compartment, but not on antigen-experienced switched memory (CD27+IgD2) B cells. Data shown as mean6 SE. C, In vivo cell turnover was
estimated by Ki67 staining of freshly isolated PBMCs. Representative flow cytofluorimetric analysis showing Ki67 binding gated on total B cells,
CD272 and CD27+ B cells, as indicated; comparison between one HC (upper row) and one cKS patient (lower row). D, The proportion of Ki67+ cells
within total B cells, CD272 and CD27+ B cells did not differ between cKS patients (grey bars) and HCs (white bars). Data shown as mean6 SE. P-values
calculated using the Student t test for independent samples.*P,.05; **P,.01.
doi:10.1371/journal.pone.0015029.g003
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natural effector compartment, transitional, pre-naı¨ve and naı¨ve B
cells were identified as cells lacking the expression of CD27 and
further defined by the expression of CD38, CD5 and/or Ig
isotypes [23]. MZ-like B cells were identified as CD27+IgDloIgM+
[25]; these cells are a unique population with attributes of both
naı¨ve and memory B cells [36]. Within the antigen-experienced T
helper-dependent compartment, memory CD27+ B cells, includ-
ing IgM-only and switched memory B cells, as well as a subset of
CD272IgD2 memory B cells [24,25] were identified.
Our results indicated that patients with cKS, as well as HSP
controls, have a significantly higher number of circulating B cells
than HHV-8-seronegative healthy controls (HCs). We did not
observe any correlation between B cell count and the clinical stage
of KS in our patients. Neither we observed any correlation
between B cells count and HHV-8 viraemia.
The expansion of B cells in cKS patients and HSP controls was
restricted to the subsets of the preimmune/natural effector
compartment. In particular, cKS patients and HSP controls
showed an increase in transitional, pre-naı¨ve, naı¨ve and MZ-like B
cells, while all antigen-experienced memory B cell subsets
appeared unaffected. No signs of increased incidence of mono-
clonal B cell expansions were observed. B cells from cKS and HSP
subjects were not activated, but rather expressed lower levels of
costimulatory molecules than B cells from HCs, and this was
equally evident on CD272 and CD27+ cells. Furthermore, these
cells did not show increased rate of cell proliferation in either
CD272 or CD27+ subset, as assessed by Ki67 staining.
The most important finding in this study was the increased
resistance to spontaneous apoptosis that was confined to B cells of
the expanded preimmune/natural effector compartment. Multiple
HHV-8 gene products have been demonstrated to promote the
survival of infected cells by increasing resistance to apoptosis,
including latency-associated nuclear (LANA), viral Flice-inhibitory
Table 2. HHV-8 load in isolated PBMCs, B cells and non-B cells
from cKS patients and healthy HHV-8-seropositive (HSP)
controls according to their peripheral blood B cells count.
Patient Sex Age
cKS
Stagea B cell count gEqb/105cells
Percentile
103/
mmc PBMC
B
cells
non-B
cells
cKS 1 M 51 1A .75th 491.2 ,5 5.0 ,5
cKS 2 M 69 1B .75th 355.4 11.0 6.0 ,5
cKS 3 M 69 2A .75th 302.6 244.0 475.3 97.6
cKS 4 M 66 2A .75th 277.8 ,5 10.2 ,5
cKS 5 M 74 1A ,25th 90.8 ,5 15.4 ,5
cKS 6 M 75 1B ,25th 69.4 ,5 ,5 ,5
cKS 7 M 62 3A ,25th 43.9 ,5 20.0 ,5
HSP 1 M 66 .75th 297.8 ,5 ,5 ,5
HSP 2 M 77 .75th 249.7 19.3 15.3 ,5
HSP 3 M 59 .75th 244.2 ,5 ,5 ,5
HSP 4 M 63 ,25th 144.7 ,5 11.0 ,5
HSP 5 M 68 ,25th 125.5 27.0 293.6 ,5
HSP 6 M 71 ,25th 107.3 ,5 ,5 ,5
acKS patients were classified according to our classification that takes into
account the prevalent type of lesions, localization, clinical behaviour, evolutive
pattern and presence of complications.
bgEq = genome Equivalents.
doi:10.1371/journal.pone.0015029.t002
Table 1. Analysis of B cells from healthy HHV-8-seropositive (HSP) compared with HHV-8-seronegative controls (HC) and cKS
patients (cKS).
HC cKS HSP
p values
HSP vs HCb
p values
HSP vs cKSb
No. 43 47 10
Cells count (cells/mL)a
B cells 128.53612.85 234.41635.28 187.19619.26 0.0026 0.3926
CD272 B cells 85.5669.11 172.38624.30 140.6617.13 0.0012 0.3845
CD27+ B cells 42.9765.79 58.54612.21 50.3769.12 0.1374 0.2127
peripheral preimmune pools:
transitional 5.2962.03 14.6762.03 8.3961.56 0.0003 0.1891
pre-naı¨ve 6.5861.35 27.1563.73 15.4662.89 0.0023 0.2873
naı¨ve 65.769.6 98.24614.87 88.93612.81 0.0425 0.3132
MZ-like 16.5962.38 42.12612.45 22.3964.17 0.0499 0.4913
antigen-experienced pools:
IgM-only memory 1.9660.38 1.6860.26 1.8660.42 0.6289 0.2564
switched memory 24.3563.54 19.0362.23 25.565.69 0.2993 0.1155
CD272 memory 16.9562.15 14.2862.17 13.1162.43 0.3559 0.2605
B cell activation
CD80 394.28629.15 273.24622.94 272.50635.86 0.0158 0.2898
CD86 139.0266.31 116.7364.83 113.7869.63 0.0499 0.4856
aMean 6 standard error.
bMann-Whitney U test was used to detect significant differences.
doi:10.1371/journal.pone.0015029.t001
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protein (v-FLIP) and the viral chemokine ligands v-CCL1 and v-
CCL2 [4]. However, the low number of viral genomes detected in
circulating B cells of our cKS and HSP patients, which is
suggestive for a low frequency of infected cells, compared with the
magnitude of their B cell changes seems to indicate that a direct
infection of circulating B lymphocytes is not required to induce the
observed B cell changes. This seems also confirmed by the lack of
correlation that we observed between B cell alterations and B cell
HHV-8 viral load.
Indirect mechanisms should be, therefore, invoked to explain
the effects of HHV-8 on B cells. It may be hypothesized that
HHV-8 infection may perturb the homeostasis of B lymphocytes
through anti-apoptotic viral proteins, cytokines or other soluble
mediators able to affect the proliferation, differentiation, traffick-
ing and, in particular, the lifespan of B cells. These mediators can
be produced by lymphocytes, dendritic cells and macrophages in
peripheral lymphoid organs, where long-term latency is estab-
lished. Among other factors, IL-6 of either viral or human origin
may represent a good candidate factor, as it is a well defined B cell
growth factor [37] centrally involved in KS. It has proven anti-
apoptotic effects on B cells [38,39] and it is expressed by a
multitude of cell types upon HHV-8 infection [40,41]. We
ourselves previously demonstrated that dendritic cells from cKS
patients produce higher amounts of IL-6 than controls [42]. The
lack of increased human-IL-6 levels in our patients and the lack of
correlation between circulating IL-6 and B cell changes cannot
rule out either the involvement of v-IL-6 or a local effect exerted
by IL-6 within lymphoid tissues, namely the spleen.
A disruption of the balance between peripheral B cell subsets
has been described in other infectious and non infectious
pathological conditions including chronic hepatitis C virus
(HCV) infection, human immunodeficiency virus (HIV) infection
and systemic sclerosis. The mechanisms proposed to explain the
disturbance of peripheral B cell homeostasis in the above
conditions rely either on peripheral activation of B cells or to
increased serum levels of IL-7 reactive to CD4+-T cell lympho-
penia [19–21,43–46]. Because we did not observe neither B cell
activation nor increased plasmatic IL-7 in cKS and HSP patients,
we suggest that none of the mechanisms supposed to sustain B cell
changes in the above conditions could likely underlie the B cell
changes that we observed in our patients. Other factors known to
affect B cell maturation, such as B cell activating factor (BAFF), IL-
5 and IL-21 [18,47,48], were not investigated in this study.
At present, we do not have data on the clinical consequences of
the expansion of preimmune B cells in cKS patients, but long-term
follow-up studies will be needed to determine whether and how
the HHV-8-induced perturbation of B cell homeostatsis may
favour the development of HHV-8 associated lymphoproliferative
malignancies. The possible relevance of MZ-like B cell expansion
observed in our patients to the known MZ involvement that may
occur in HHV-8-related lymphoproliferative malignancies [49]
needs to be explored. Our observations, together with the recent
demonstration that MZ-like B cells are clonally expanded in a
subset of patients with chronic HCV infection [50] and support
Epstein-Barr virus (EBV) infection in different clinical settings
[51,52], may all provide important cues for further investigation of
the mechanisms possibly used by lymphotropic viruses to promote
the development of lymphoproliferative disorders.
In conclusion in this study we report, for the first time to our
knowledge, that HHV-8 chronic infection promotes a profound
perturbation of peripheral B cell homeostasis characterized by
expansion of B cells of the preimmune/natural effector compart-
ment, in patients with cKS without clinical signs of humoral
immune deficiency. This novel observation may broaden our
understanding of the complex interplay of viral and cellular factors
leading HHV-8-infected individuals to develop either KS or
lymphoproliferative malignancies. Perspectively, long-term follow-
up analysis of peripheral B cell changes in cKS patients will greatly
help the comprehension of the mechanisms of viral tumorigenesis
and possibly enable the development of efficient targeted
therapies.
Materials and Methods
Patients and controls
Forty-seven cKS patients were included in the study, 39 males
and 8 females, mean age 72 years (range 49–95). All patients had
histologically confirmed diagnosis of KS, were positive for anti-
HHV-8 antibody and negative for HIV. Staging was performed in
accordance with our classification that takes into account the
prevalent type of lesions, localization, clinical behavior, evolutive
pattern, and presence of complications [53,54]. Patients in
systemic chemotherapy were excluded. B cells characterization
was performed at a single time point on fresh peripheral blood
samples; staging at this time is reported in Table 3. Forty-three
age- and sex-matched healthy HHV-8-seronegative subjects were
included as controls (HC). Ten age- and sex-matched healthy
HHV-8-seropositive (HSP) controls without KS were also
enrolled. None of the subjects had suffered from chronic
inflammatory, autoimmune and cancer disease other than KS,
nor they had clinically evident infections. Peripheral blood samples
were obtained by venipuncture and collected into sodium citrate
Vacutainer tubes (Becton Dickinson, San Jose, CA, USA).
Ethics statement. Ethics approval was obtained from the
Ethics Committee of the Fondazione Istituto di Ricovero e Cura
a Carattere Scientifico Ca’ Granda Ospedale Maggiore Policli-
nico, and written informed consent was provided by study
participants.
Table 3. Clinical characteristics of cKS patients.
Characteristics Overall patients Evolutive pattern
No. of patients 47
Age, yra 72.261.4
Sex, no.
Male 39
Female 8
KS stageb, no.
A (slow) B (rapid)
I: maculo-nodular 29 15 14
II: infiltrative 11 4 7
III: florid 4 1 3
IV: disseminated 3 0 3
Total 20 27
aMean 6 standard error.
bcKS patients were classified according to our classification that takes into
account the prevalent type of lesions, localization, clinical behaviour, evolutive
pattern and presence of complications (53,54).
A indicates slow evolution; B, rapid evolution; rapid denotes an increase in the
total number of nodules/plaques or in the total area of plaques in three months
following the last examination.
doi:10.1371/journal.pone.0015029.t003
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Clinical tests
All patients and controls underwent a detailed clinical,
haematological and biochemical examination. Plasmatic HHV-8
DNA was quantified in clinical laboratories by HHV-8 Q-PCR
Alert Kit (Nanogen Advanced Diagnostics, Milan, Italy), accord-
ing to the manufacturer’s instructions; results were expressed in
genome Equivalents (gEq). Anti-HHV-8 specific IgG antibodies
were tested in serum samples using a commercial immunofluo-
rescence assay (HHV-8 IgG IFA, Biotrin, Ireland).
Immunophenotypic analysis of B lymphocytes
Whole peripheral blood (PB) samples were processed within
6 hours after blood withdrawal. 100 ml of PB were washed twice in
PBS with 1% bovine serum albumin (BSA) and then incubated in
fetal bovine serum (FBS) for 30 min at 37uC. Then, PB samples
were stained with various monoclonal antibody (mAb) combina-
tions for 20 min at RT. The following directly conjugated mouse
anti-human mAbs were used at optimal concentrations: CD5-
allophycocyanin (APC), CD19-peridinin chlorophyll protein
(PerCP)-Cyanin (Cy)5.5, CD80-phycoerythrin (PE), CD86-fluo-
rescein isothiocyanate (FITC) (all from BD Biosciences, San Jose,
CA, USA); CD20-PE-Cy7 and CD27-APC-Cy7 (from eBio-
ciences, San Diego, CA); CD38-PE (Dako, Glosturp, Denmark);
IgD-FITC and IgM-PE (from Serotec, Oxford, UK); k light chain-
FITC and l light chain-PE (from Miltenyi-Biotec GmbH,
Germany); HLA-DR-PE (from Caltag Laboratories, Burlingame,
CA). After incubation, erythrocytes were lysed by incubation with
ammonium chloride for 10 min at 4uC in the dark. Six-color data
acquisition and analysis were performed on a FACSCanto2 flow
cytometer (Becton Dickinson) using a FACSDiva software (v6.1)
immediately after staining. As isotype controls were not used, those
cells that did not express a certain marker were considered as
negative control for positive cells [55]. Lymphocytes were gated on
forward (FSC) vs side scatter (SSC) plots and B lymphocytes were
identified as cells positive for CD19 expression. At least 100,000
lymphocyte-gated cells were routinely collected for each sample.
Estimates of the absolute numbers of B cells and their subsets were
calculated from the proportion of cells recorded by flow cytometry
in the lymphocyte gate multiplied by absolute lymphocyte count
measured using a standard hemacytometer.
Assessment of spontaneous apoptosis of B cell subsets
The sensitivity of B cell subsets to spontaneous apoptosis was
evaluated in cultured cells, as described [30,56]. Isolated PBMCs
from 6 cKS patients and 6 HHV-8-seronegative healthy controls
were cultured in 24-well plated for 24 h in RPMI 1640
(Euroclone, Wetherby, UK) containing 10% fetal calf serum
(Gibco, Invitrogen Co., Carlsbad, CA, USA) and incubated in a
5% CO2 incubator at 37uC for 24 hours. Cells were harvested and
stained for flow cytometric analysis using an annexin-V APC
apoptosis detection kit (BD Pharmingen, San Jose, CA, USA) in
combination with anti-CD19-PerCP-Cy5.5, anti-CD27-PE (BD
Biosciences) and anti-IgD-FITC (Serotec). Apoptotic cells were
identified as annexin-V+ cells gated on different B cell subsets.
Ex vivo Ki67 staining
PBMCs from 6 cKS patients and 6 HHV-8-seronegative
healthy controls were stained for flow cytometric analysis with
anti-CD19-PerCP-Cy5.5 anti-CD27-PE (BD Biosciences). Sam-
ples were then fixed, permeabilised and stained for the cell cycle-
associated antigen Ki67 (FITC-labeled B56; BD Biosciences),
using the Leucoperm Reagent (AbD Serotec), according to the
manufacturer’s instructions. Cells that had recently divided were
identified as Ki67+ cells and provided an estimate of the in vivo cell
turnover.
Isolation of human B cells
B lymphocytes were isolated from 7 cKS patients and 6 HSP
controls, chosen among subjects with B cell count either over the
75th percentile or under the 25th percentile calculated for each
group. Peripheral blood mononuclear cells (PBMCs) were
obtained by Ficoll density gradient centrifugation (Ficoll-Hypaque
Pharmacia Biotech AB, Sweden). CD19+ cells were purified using
immunomagnetic selection with mini-MACS cell isolation Kit
(Milteny-Biotec) according to the manufacturer’s instructions.
Total PBMCs, B cells and non-B cells were further processed for
virological analyses.
Assessment of HHV-8 infection in isolated cells
Isolated PBMCs, B cells and non-B cells from 7 cKS patients
and 6 HSP controls were tested for the presence and load of
HHV-8 DNA sequences, as previously described [8,57]. Briefly,
DNA was extracted from at least 26105 cells, and HHV-8 viral
load was measured by quantitative real-time polymerase chain
reaction (PCR), and results were reported as gEq/105 cells.
IL-6 and IL-7 measurement in plasma samples
Plasma samples were obtained under sterile conditions from
single donors. The amounts of plasmatic IL-6 and IL-7 were
determined by ELISA kits from R&D Systems (Minneapolis, MN).
All individual steps were performed according to the manufactur-
er’s instructions.
Statistical analysis
Data are presented as mean 6 SE. Comparisons of samples to
establish the statistical significance of difference were determined
by the Student t test for independent samples. The Mann-Whitney
U test was also used when indicated. All statistical analyses
assumed a 2-sided significance level of 0.05. Data analyses were
performed with Openstat3 software.
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